(Q44554932)

English

Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study

scientific article published on 17 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

quality of life

1 reference

based on heuristic

inferred from title

author name string

K A Papp

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

M Sundaram

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Y Bao

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

D A Williams

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Y Gu

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

J E Signorovitch

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Y Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

J M Valdes

8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

P M Mulani

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

publication date

17 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Journal of the European Academy of Dermatology and Venereology

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

790-798

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

The prevalence of psoriasis in the world

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Quality of life in patients with psoriasis: a systematic literature review

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Psoriasis causes as much disability as other major medical diseases

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Health-related quality of life is related to COPD disease severity

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Measuring disability and quality of life in established rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Development, cytokine profile and function of human interleukin 17-producing helper T cells

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

10 years experience of the Dermatology Life Quality Index (DLQI).

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

A randomized trial of etanercept as monotherapy for psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.12177

21 January 2018

Identifiers

10.1111/JDV.12177

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44554932&oldid=2027718088"